{"name":"Gannex Pharma Co., Ltd.","slug":"gannex-pharma-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"ASC 41","genericName":"ASC 41","slug":"asc-41","indication":"Other","status":"phase_1"},{"name":"ASC42 5 mg","genericName":"ASC42 5 mg","slug":"asc42-5-mg","indication":"Other","status":"phase_2"},{"name":"ASC43F","genericName":"ASC43F","slug":"asc43f","indication":"Other","status":"phase_1"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ASC42","genericName":"ASC42","slug":"asc42","indication":"Non-alcoholic steatohepatitis (NASH)","status":"phase_1"}]}],"pipeline":[{"name":"ASC 41","genericName":"ASC 41","slug":"asc-41","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASC42","genericName":"ASC42","slug":"asc42","phase":"phase_1","mechanism":"ASC42 is a potent and selective FXR agonist that modulates bile acid metabolism and inflammation.","indications":["Non-alcoholic steatohepatitis (NASH)"],"catalyst":""},{"name":"ASC42 5 mg","genericName":"ASC42 5 mg","slug":"asc42-5-mg","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASC43F","genericName":"ASC43F","slug":"asc43f","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPeEFsSF9EMzRnbHdNQ01ZODhHRjhzbEZGNThOUHZpM3pKV2JfWDZaSC1OUUgybnczamVxejktcXFVR1o4aU9Va1ZzdUw1X1B1SmU0aVdWUDlkYjVMRVJjY1N2d0ZJRkE0S01TczRmXzJPQ0NHQmxVTXVSR2pRcDVWMmhsMXNJa2o3M0pXNFREb19lOEsx?oc=5","date":"2026-04-06","type":"pipeline","source":"openPR.com","summary":"Primary Biliary Cholangitis Market Outlook 2034: Growth - openPR.com","headline":"Primary Biliary Cholangitis Market Outlook 2034: Growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAJBVV95cUxQSm1Cc0dfSDV6ZnZ3dU9sQ3B6YWtTUEpkVi1UVXE3aGRTVWdjVklnN19nSnUtS2p6ckhwZ1RxdEJhTlZTZEhxMl8xdlRSVzg5LUc1TWRtMUxJMXAwdl9KazVFOG9RYjJ1RmdSNnpjOW9qUVAxWmd6c01vQU1pZE1XTlJOZmdTbEdWZjJkM3ZESDBvd251SWRiYVZCaFpQbXN3aWJTdWdaT3FWVHJaRTZSY1poMVBhX0d4NS1RaFJIbkpNRTVCSFpOZVFVZDNkRnl0QVRFNmtQY2taSnY5a3BSSDgzVHZYcHRjeDBEd21yS2E1VFdFenk5dWNQcklkLWll?oc=5","date":"2026-03-02","type":"trial","source":"Barchart.com","summary":"Non-Alcoholic Steatohepatitis Clinical Trial Pipeline Expands as 70+ Companies Driving Innovation in the Therapeutics | DelveInsight - Barchart.com","headline":"Non-Alcoholic Steatohepatitis Clinical Trial Pipeline Expands as 70+ Companies Driving Innovation in the Therapeutics | ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPSGpZLW5hN21yU25obUF4Y0dfU2pLRlRvRWJ2NUhITlg4NXJ6Z0tBdmJZOUI0MW9lVzJ3U0t0TGowdEwycE5WV2NUYjZRYktTU2NEYWhwMEFjU21PRFluWldIOVNhRHN6UjZyakI5MHhodXJIWHpmQXE1cUg0UkhVcnhYVUtPYTBpLU1SdUpYODg2RlNyNV9DRzR4Nkw3LTN6U3pHR0JlVQ?oc=5","date":"2024-09-19","type":"trial","source":"BioWorld News","summary":"Hark, Herald MASH phase II positive but Aligos THRown for a loop - BioWorld News","headline":"Hark, Herald MASH phase II positive but Aligos THRown for a loop","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxPTm1iOVZkUkcwdDV3cF90OEpGZ3VLbGdJQ0ZaWDNFa3BlMUF0ZS1CUTB5TWV2eHlFbkh1cXl6RjJFaHZlR1RVLVNTd1FDM19RRExiaEJIYndWWEk5ekp5aUlXNXRNbXFIYkFFUDlhOGdSRlRNZDlSN2IwekIyZ0ZES1FfdTVFY0JacTY3Z3Q3WE9kbUtERl9kVlFIY3Yzd2pqN19Wc1VHeHhNNU9ZZF9wa29qeDNDZC1wVFRFOGVSQTlRdTNNem5XRnJWR1lLNkRJOXBIZ2lSd0E0WU44dXhaaVo1dlkwdjR2Q3F6bUZkM3JkamtCTVYyMEhDQVRZLXBqd0VHWGctQmtLb2tyaC1mSk9RcEZVZ2RtUzdQZDRVcW9oLUV1VHMwbnVvczVlUUFTX3dz?oc=5","date":"2024-07-23","type":"trial","source":"GlobeNewswire","summary":"GLP Agonist Clinical Trial Pipeline Appears Robust With 20+ - GlobeNewswire","headline":"GLP Agonist Clinical Trial Pipeline Appears Robust With 20+","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-06-18","type":"pipeline","source":"PR Newswire","summary":"Obesity Market to Observe Impressive Growth by 2034, Assesses DelveInsight | Key Companies - Novo Nordisk A/S, Pfizer, Boehringer Ingelheim, Eli Lilly and Company, Rhythm Pharmaceuticals, Harmony Bios","headline":"Obesity Market to Observe Impressive Growth by 2034, Assesses DelveInsight | Key Companies - Novo Nordisk A/S, Pfizer, B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPN3hqc0ZlUG9MWV96eUQ3RWlSdXNLMVJfTHlVYi0yZFNTb0tuYi1iTTYyVFJrZDNVM21FUVJfbXJ4OFBsNHN5cVJ3MTRoVHlwZHM3Sm1idG5lTzV5aWtFRkU1RUNXeEJWVm9YRnFYUmYzVUpnckFBeldiTmVtNU5ncGpLX3lXWUMzOTEyMHRGTXVBQQ?oc=5","date":"2024-03-25","type":"trial","source":"Yahoo Finance","summary":"Cirrhosis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight - Yahoo Finance","headline":"Cirrhosis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxPOXduWVp5b19OWFd5R1BzMkZvcldONC0xVEc3NTh1aEhJLU5HV1Q0Ni0zZlVxUGFzemZoRzBWdmVPOUJ0eXVnZVdKeGtQVTlQMmJNdEwzaWptc2puZTg2dFM5Vkk1XzlUX3R6bjllTTRVeGhzcGlzVTdkNXk0amx3bS1HWUY1UHdWOFlCNnhqS2ZlLVVhRmdHQWhDV3VncVRDcUlpUnU5b204Q3BEazN3bXRBclJZdDByMjQxNDZCX3RIWG9UVWc3YlV6Uk9UWGUyeGUyUmhlbEV0ZjVfYlJmbGVYMDR5YXBFeXAw?oc=5","date":"2023-07-12","type":"pipeline","source":"PR Newswire","summary":"Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight - PR Newswire","headline":"Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNd1N1V2JXbDBFcTZxWW9LMVI1WlRhdEhyWjlMVHdPa2h2OVZBWU55b1EwQ0hrNVhUTTFDeTR2Z2o5dTRXNWdLMVJKSGZfUExsWklmcTZRY2QzWVVHcWxUbXRNYlFUbmx0RGZ0N3hhcjR2YS1WMV9HSVp2ajE2VWR0RnFVQ0tQNFAyTUl6Mm9oV3l0a2djcS1KMFpQRlVsTm1oS2lMSDVVNXdvbE9jUnc3Q01R?oc=5","date":"2023-01-03","type":"pipeline","source":"Fierce Biotech","summary":"Viking accuses Chinese biotech of 'ruse' to raid trade secrets and make off with NASH cache - Fierce Biotech","headline":"Viking accuses Chinese biotech of 'ruse' to raid trade secrets and make off with NASH cache","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxNblhYaFFETW8zVGd1UzNzU2Zwc0dIR0dZMlFsM0Z1UTBfMXhlQW12QnJVenFTT0RfRjYzRklqazh5Q25zc2g5X3hVaE0tbzJFYU5VWHpQSU0yYjZERnNWUHhhMGw0SnJWeGNuMWJld3ptTFFMQXV4Um5CTlFlZ0FmRGVRWHhMQjh5ZHNmaVE0SmRpZG44Vkhoai1YdTZUNU9iMUlTN3ZPc2tUMXdTNWtyaFMxRlU3M2xSdGJVdVBEenFXRzlRNUpQTVJLelBYZw?oc=5","date":"2022-12-29","type":"pipeline","source":"Reuters","summary":"Viking Therapeutics accuses Chinese co of stealing fatty liver disease drug secrets - Reuters","headline":"Viking Therapeutics accuses Chinese co of stealing fatty liver disease drug secrets","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOMThlSG16TDVzU3NVZW9BSEJQclJJYXB6cnpJam1aNU5rYWJJMlBwcmlMNm1ScG9ITkQ2X09RNk5DXzFVME84ZEhOYzJ5aUZFYlBaZkpnbW0wb1E0SXpLcngwbUdCekdTOWs3amc4RlAyNHJwQ01NZXpnNmhUa0UzaHBDaWdsOUlxTEEyLVdaRDEtU1k?oc=5","date":"2020-10-13","type":"deal","source":"BioWorld News","summary":"Galmed partners with Gannex to develop NASH cure - BioWorld News","headline":"Galmed partners with Gannex to develop NASH cure","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_1":3,"phase_2":1},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}